Amendment #8 to S2142

Patient Access to Abuse-Deterrent Formulations

Mr. Sánchez of Boston moves to amend the bill in section 9 by inserting after the word “section.”, in line 108, the following words:--  "Coverage of said abuse-deterrent formulation opioid drug products shall not be subject to any prior authorization, step-therapy, or quantity limit that does not apply to non-abuse-deterrent formulation opioid medications in the same opioid class.”;

And further moves to amend the bill in section 20 by inserting after the word “section.”, in line 254, the following words:--  "Coverage of said abuse-deterrent formulation opioid drug products shall not be subject to any prior authorization, step-therapy, or quantity limit that does not apply to non-abuse-deterrent formulation opioid medications in the same opioid class.”;

And further moves to amend the bill in section 22 by inserting after the word “section.”, in line 292, the following words:--  "Coverage of said abuse-deterrent formulation opioid drug products shall not be subject to any prior authorization, step-therapy, or quantity limit that does not apply to non-abuse-deterrent formulation opioid medications in the same opioid class.”;

And further moves to amend the bill in section 24 by inserting after the word “section.”, in line 332, the following words:--  "Coverage of said abuse-deterrent formulation opioid drug products shall not be subject to any prior authorization, step-therapy, or quantity limit that does not apply to non-abuse-deterrent formulation opioid medications in the same opioid class.”;

And further moves to amend the bill in section 26 by inserting after the word “section.”, in line 371, the following words:--  "Coverage of said abuse-deterrent formulation opioid drug products shall not be subject to any prior authorization, step-therapy, or quantity limit that does not apply to non-abuse-deterrent formulation opioid medications in the same opioid class.”.